Market Place
Sourcing Support
Publishes Ph 3 Results for Roche’s Itovebi in HR+ve Breast Cancer
31 Oct 2024 //
GLOBENEWSWIRE
Synthon Pharms Generic Palbociclib Receives Approval in US
05 Jun 2024 //
FDA
Roche’s PI3K inhibitor wins FDA priority review for breast cancer
30 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Arvinas & Pfizer announce updated clinical data from Ph1b Trial of Vepdegestrant
18 May 2024 //
INDINPHARMAPOST
Pfizer, Arvinas’ breast cancer drug combo keeps momentum after Phase 1b update
16 May 2024 //
ENDPTS
AbbVie`s Humira, J&J`s Darzalex top ICER`s annual price-hike list
11 Dec 2023 //
FIERCE PHARMA
Roche`s inavolisib combo cuts breast cancer progression by 57%
09 Dec 2023 //
PRESS RELEASE
Olema Announces Palazestrant Demonstrates Combinability with CDK4/6 Inhibitors
05 Dec 2023 //
GLOBENEWSWIRE
Olema Oncology to Present at the 2023 Jefferies Healthcare Conference
30 May 2023 //
GLOBENEWSWIRE
Bristol Myers, Pfizer, AbbVie drugs likely to face U.S. price negotiation
14 Mar 2023 //
REUTERS
Pfizer unveils mysterious Ibrance breast cancer nod
01 Feb 2023 //
FIERCE PHARMA
MSN Group launches world’s first generic drug for advanced breast cancer therapy
19 Jan 2023 //
BIOSPECTRUMASIA
Dr. Reddy’s acquires trademark rights of breast cancer drug PRIMCYV from Pfizer
14 Jan 2023 //
INDIAN PHARMA POST
Sun launches Palbociclib, a novel targeted therapy for advanced breast cancer
12 Jan 2023 //
INDIANPHARMAPOST
Pharma companies boost drug prices to start year, but hikes lag inflation
04 Jan 2023 //
BIOPHARMADIVE
Olema Oncology Announces OP-1250 Attractive with CDK 4/6 Inhibitor Palbociclib
07 Dec 2022 //
GLOBENEWSWIRE
Erasca Announces Trial Collaboration with Pfizer to Evaluate ERAS-007
20 Oct 2022 //
GLOBENEWSWIRE
UK NICE grants approval for breast cancer drug combination
26 Sep 2022 //
PHARMACEUTICAL-TECHNOLOGY
Amber Specialty Added to Pfizer’s Limited Distribution Network
03 Aug 2022 //
BUSINESSWIRE
Eugia Pharma Generic Palbociclib Receives Approval in US
07 Jul 2022 //
FDA
Lilly`s Verzenio wins NICE backing in adjuvant breast cancer
22 Jun 2022 //
FIERCEPHARMA
Pfizer`s Ibrance fails to extend lives in 1L breast cancer
06 Jun 2022 //
FIERCEPHARMA
Ibrance improves survival in breast cancer patients
10 May 2022 //
EUROPEANPHARMACEUTICALREVIEW
Data Showing Tvardi’s TTI-101 Overcomes Palbociclib Resistance in mBC Models
07 Apr 2022 //
BUSINESSWIRE
FDA posts guidance on mining real-world data from health records
29 Sep 2021 //
PHARMAPHORUM
Novartis & SOLTI collaborate on HARMONIA, phase III study of Kisqali vs Ibrance
21 Sep 2021 //
PHARMABIZ
Dr. Reddy`s Generic Palbociclib Receives Tentative Approval In the US
20 Aug 2021 //
FDA
Potential new treatment for deadly blood cancer
12 Aug 2021 //
SCIENCEDAILY
Progress on metastatic breast cancer programme
14 Jun 2021 //
SHARECAST
Pfizer leans on Ibrance real-world breast cancer win
27 Mar 2021 //
FIERCE PHARMA
Adjuvant Palbociclib Fails in Early, High-Risk Breast Cancer
11 Dec 2020 //
MEDPAGETODAY
Novartis` CDK4/6 med Kisqali, firmly the sales underdog against Pfizer
10 Dec 2020 //
ENDPTS
Pfizer moves US court against Aurobindo Pharma, Dr Reddy`s on Cancer drug
18 Nov 2020 //
ECONOMIC TIMES
Olema Oncology Announces Clinical Trial Agreement to Evaluate OP-1250
13 Nov 2020 //
PRNEWSWIRE
Calithera Announces Expansion of Ongoing Trial Evaluating Telaglenastat
04 Nov 2020 //
GLOBENEWSWIRE
Pfizer`s Ibrance fails to hit main goal of early breast cancer study
10 Oct 2020 //
REUTERS
PENELOPE-B Trial of IBRANCE® in Early Breast Cancer Did Not Meet Primary
09 Oct 2020 //
BUSINESSWIRE
Zydus Cadila receives tentative approval from USFDA for Palbociclib Capsules
24 Sep 2020 //
PRESS RELEASE
Zydus Cadila gets tentative USFDA nod to market anti-cancer drug
23 Sep 2020 //
MONEY CONTROL
Vyndaqel, Ibrance boost Pfizer as it eyes COVID-19 shot launch
29 Jul 2020 //
FIERCE PHARMA
Pfizer declines about 8% after setback to breast cancer treatment
01 Jun 2020 //
REUTERS
Pfizer Provides Update on Ph3 PALLAS Trial of IBRANCE® (palbociclib)
29 May 2020 //
BUSINESSWIRE
Pfizer to present clinical trials of 18 approved & investigational medicines
13 May 2020 //
PHARMABIZ
New Data from 18 Approved and Invg Pfizer Medicines to be Showcased at ASCO20
12 May 2020 //
PRESS RELEASE
AllianceRx Walgreens Prime studies the use of cyclin kinase 4/6 inhibs
11 May 2020 //
PR NEWSWIRE
Alphamab Oncology Announces Clinical Supply Collaboration with Pfizer on KN026
27 Mar 2020 //
PR NEWSWIRE
Merck`s Keytruda faces NICE pushback as Ibrance, Lynparza grab green lights
16 Jan 2020 //
FIERCE PHARMA
Pfizer backs Ibrance with real-world breast cancer data
12 Dec 2019 //
FIERCE PHARMA
NICE approves Ibrance via Cancer Drugs Fund
28 Nov 2019 //
PHARMA TIMES
Pfizer’s Ibrance approved by NICE, to be added to the Cancer Drugs Fund
28 Nov 2019 //
PHARMA FILE
Novartis, Eli Lilly marquee positive survival data for CDK 4/6 franchises
29 Sep 2019 //
ENDPTS
Pfizer Presents New Evidence of IBRANCE® palbociclib Effectiveness in HR+, HER2
24 Sep 2019 //
PRESS RELEASE
Half of European cancer drug trials ‘biased’, says BMJ
21 Sep 2019 //
PMLIVE
FDA Warns of Possible Interstitial Lung Disease, Pneumonitis,Breast Cancer Drugs
16 Sep 2019 //
CANCERTHERAPYADVISOR
Three Breast Cancer Drugs: FDA Warns of Rare but Serious Lung Inflammation
13 Sep 2019 //
RAPS
Novartis’ Kisqali, trailing Lilly’s Verzenio, nabs limited NICE backing
17 Jul 2019 //
FIERCE PHARMA
Pairing targeted drugs could overcome breast, lung cancer treatment resistance
11 Jul 2019 //
PHARMATIMES
